Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5400545 | 0.78 | SOAT1 (0.34) | SOAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5411148 | 0.64 | SOAT1 (0.32) | SOAT1 | |
| SCHEMBL13637824 | 0.61 | — | — | |
| SCHEMBL4263862 | 0.60 | NPC1 (0.51) | SOAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9016629 | 0.59 | — | — | |
| SCHEMBL18119744 | 0.58 | SMN1; SMN2 (0.62) | SOAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4263866 | 0.58 | SMN1; SMN2 (0.46) | SOAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24022680 | 0.56 | SMN1; SMN2 (0.42) | SOAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18119745 | 0.56 | SMN1; SMN2 (0.54) | SOAT1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24248562 | 0.55 | SMN1; SMN2 (0.36) | SOAT1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | SOAT1 4581/4885NPC1 822/4885RAB9A 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.